IL1RAP ADC / Cantargia, AbbVie - LARVOL DELTA

IL1RAP-targeting antibody-drug conjugate: a novel therapeutic targeting both tumor cells and the tumor microenvironment (AACR 2025) - "The selected clone showed low nanomolar affinity to human (KD 4.9nM) and cynomolgus (KD 5.4nM) IL1RAP, strong binding to IL1RAP-expressing cells (IC50 6.9nM) and robust internalization in IL1RAP-expressing cells. Conjugation to the payload did not compromise binding of the antibody to IL1RAP-expressing cells. In vitro, the IL1RAP-targeting ADC showed IL1RAP-dependent cell killing."

Biomarker • Tumor cell • Tumor microenvironment • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • IL1RAP

Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference (ACCESSWIRE) - "Cantargia...released a poster with new preclinical data that strengthens the rationale behind the development of novel anti-IL1RAP ADCs....The poster is presented at the American Association for Cancer Research (AACR) Annual Meeting....Preclinical data on the novel anti-IL1RAP ADC shows effective tumor growth inhibition with potent dose-dependent anti-tumor activity in a high IL1RAP expressing tumor model. Notably, a single dose of the ADC led to long-lasting efficacy, demonstrating 100% survival by day 95 in the high target expression model, compared to 60% in animals treated with a control ADC (non-targeting antibody conjugated to the same linker-payload)."

Preclinical • Solid Tumor

Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025 (Cantargia Press Release) - "Cantargia...announced an upcoming presentation of preclinical data on the development of IL1RAP-targeting antibody-drug conjugates (ADCs)....The findings demonstrated safety, tolerability, and significant anti-tumor efficacy of IL1RAP targeting ADCs in preclinical animal models, suggesting promising therapeutic potential across a broad range of cancers expressing ILRAP."

Preclinical • Solid Tumor